COVID-19 risk with nebulisers, fewer hospitalisations and community cases in the UK, variant under investigation B.1.617 (India)

Peer reviewed journals featured:

- A systematic review on the risk of transmitting COVID-19 during nebuliser treatment [here](#)
- Observational studies on:
  - First-dose vaccination roll-out and COVID-19 hospital admissions in Scotland [here](#) and associated commentary [here](#)
  - COVID-19 vaccine coverage in healthcare workers and effectiveness of Pfizer vaccine against infection in England [here](#) and associated commentary [here](#)
  - Household exposure to SARS-CoV-2 and association with COVID-19 severity in Denmark [here](#)
  - Cerebral venous thrombosis among COVID-19 patients in New York [here](#)
  - Topics and sentiments on COVID-19 vaccination from Twitter users in Australia [here](#)
- Case reports on:
  - Guillain-Barre syndrome following the first dose of AstraZeneca vaccine [here](#)
  - Painless idiopathic neuralgic amyotrophy after COVID-19 vaccination [here](#)

Letters and correspondence discussed:

- Low immunisation rates in kidney transplant recipients after 2 doses of the Moderna vaccine [here](#)
- Antibody responses to COVID-19 vaccination in patients receiving dialysis [here](#), [here](#), [here](#) and [here](#)

Pre-peer review articles featured:

- The impact of vaccination on SARS-CoV-2 cases in the community in the UK [here](#)
- The frequency of neurological manifestations in COVID-19 [here](#)
- Neutralisation of variant under investigation B.1.617 (India) with sera of BBV152 (Covaxin) vaccinees [here](#)
- Cerebral venous sinus thrombosis and COVID-19 vaccines in the US [here](#)
- Effectiveness of COVID-19 mRNA vaccines against hospitalisations and deaths in the US [here](#)
- Protection from prior SARS-CoV-2 infection and vaccination in Israel [here](#)
- The impact of SARS-CoV-2 vaccines on antibody responses in the UK [here](#)
Guidance and reports

- The World Health Organization published a webinar report on expanding our understanding of post-COVID-19 condition [here](#).
- A Eurosurveillance report on SARS-CoV-2 variants of concern B.1.1.7 (UK), B.1.351 (South Africa), and P.1 (Brazil) [here](#).

Click [here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern.

---

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.